Physician
Optimal Pain and Wellness
Optimal Pain and Wellness was paid $1.96M by Medicaid between Jan 2018 and Oct 2024, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoOPTIMAL PAIN AND WELLNESS
FAYETTEVILLE, AR 72703
FAYETTEVILLE, AR 72703
33aNPI1487920146assigned 03/28/2012
33bProvider typePhysical Medicine & Rehabilitation Physician
28Total paid$1.96M
24GClaims246,602
24DCodes billed58
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Physical Medicine & Rehabilitation Physician providers in Arkansas
Rank by total paid#2 of 30
Median peer was paid$8K
This provider vs. median241×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,469 | $430K | |
| 2019 | 41,311 | $309K | |
| 2020 | 33,766 | $264K | |
| 2021 | 36,992 | $273K | |
| 2022 | 32,922 | $256K | |
| 2023 | 32,248 | $229K | |
| 2024incomplete | 24,894 | $196K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 19,433 | 18,396 | $472K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.9% | 5,103 | 4,911 | $97K |
| 80373 | 4.7% | 9,743 | 9,413 | $92K | |
| 80354 | 4.5% | 9,711 | 9,382 | $89K | |
| 80369 | 4.4% | 9,742 | 9,412 | $86K | |
| 80365 | 4.4% | 9,718 | 9,387 | $86K | |
| 80356 | 4.3% | 9,342 | 9,020 | $85K | |
| 80362 | 4.0% | 9,451 | 9,133 | $79K | |
| 80348 | 4.0% | 9,426 | 9,109 | $79K | |
| 80372 | 3.9% | 9,728 | 9,396 | $76K | |
| 80335 | 3.3% | 9,446 | 9,125 | $64K | |
| 80355 | 3.1% | 9,464 | 9,145 | $61K |
46 more codes
| 80358 | 3.0% | 8,951 | $60K | |
| 80305 | 3.0% | 16,729 | $58K | |
| 80350 | 2.9% | 8,633 | $58K | |
| 80366 | 2.8% | 9,449 | $54K | |
| 80346 | 2.4% | 5,941 | $48K | |
| 80367 | 2.1% | 9,370 | $41K | |
| 80359 | 2.1% | 8,633 | $41K | |
| 80323 | 2.0% | 3,315 | $38K | |
| 80357 | 1.8% | 8,385 | $36K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,091 | $25K |
| 80371 | 1.2% | 6,027 | $24K | |
| 80345 | <1% | 3,047 | $19K | |
| 80338 | <1% | 3,049 | $19K | |
| 80360 | <1% | 3,050 | $15K | |
| 96367 | <1% | 1,085 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,732 | $12K |
| 83992 | <1% | 2,602 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 153 | $8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 9,620 | $6K |
| 80324 | <1% | 1,348 | $2K | |
| 80364 | <1% | 243 | $1K | |
| 80353 | <1% | 261 | $814.20 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 83 | $743.75 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 426 | $600.00 |
| 62369 | <1% | 28 | $497.88 | |
| 76942 | <1% | 26 | $455.16 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 228 | $243.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30 | $185.64 |
| 84311 | <1% | 186 | $27.43 | |
| 99443 | <1% | 126 | $20.34 | |
| 83986 | <1% | 186 | $15.12 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,260 | $6.87 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 788 | $0.00 |
| 3725F | 0% | 797 | $0.00 | |
| 1124F | 0% | 620 | $0.00 | |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 120 | $0.00 |
| 1100F | 0% | 123 | $0.00 | |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 78 | $0.00 |
| L0651 | Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf | 0% | 22 | $0.00 |
| 90791 | Psychiatric diagnostic evaluation | 0% | 193 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 865 | $0.00 |
| G2197 | Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user | 0% | 736 | $0.00 |
| M1207 | Patient is screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety | 0% | 811 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 322 | $0.00 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 264 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 263 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHURMAN, REGINA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Optimal Pain and Wellness | Fayetteville, AR | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.